BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc. (VTAE) Release: BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation 2/27/2015
Boehringer Ingelheim Puts Hold on Key Alzheimer's Drug Trial 2/27/2015
INSYS Therapeutics Announces Its Pharmaceutical Cannabidiol Received Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
Sangamo BioSciences (SGMO) Presents New Clinical Data At CROI 2015 From Trial Of ZFP Therapeutic Designed To Provide Functional Control Of HIV 2/26/2015
ObsEva Reports Positive Phase 1 Results For The First Orally Active Oxytocin Antagonist OBE001 To Treat Preterm Labour 2/26/2015
Innocrin Pharmaceuticals Inc. To Present Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study And Preclinical Results That Demonstrate VT-464 Efficacy In A Clinically-Relevant Enzalutamide-Resistant Mouse Model 2/26/2015
Ampio Pharmaceuticals, Inc. (AMPE) Announces Top-Line Results Of The Double-Blind Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Moderate To Severe Osteoarthritis Of The Knee 2/25/2015
Anavex (AVXL) Release: ANAVEX 2-73 Could Prevent Alzheimer's Disease In Addition To Modifying And Treating Symptoms 2/25/2015
Cell MedX Corp. (CMXC) Announces Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 2/25/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Beclomethasone Dipropionate HFA Product 2/24/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions In Prekallikrein Levels 2/24/2015
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015
BioTime (BTX) Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy 2/24/2015
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015
Arrowhead Research Corporation (ARWR) Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency 2/23/2015
ReveraGen BioPharma Announces Start Of Phase 1 Clinical Trial Of VBP15 Dissociative Steroid Drug 2/18/2015
Dipexium Pharmaceuticals (DPRX) Announces Successful Completion And Initial Results Of Phase 1 Skin Sensitization Trial Of Locilex 2/17/2015
Helix Biopharma (TSX:HBP) Initiates Enrollment for Eleventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 2/17/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant 2/17/2015
Stealth Biotherapeutics Initiates A Clinical Study Of Bendavia For The Treatment Of Orphan Mitochondrial Diseases 2/17/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Colorectal Cancer 2/17/2015
Anaheim Clinical Trials (ACT) ‘Slam Dunks’ Enrollment On Another Japanese Bridging Study 2/16/2015
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1690 2/16/2015
Bexion Pharmaceuticals Receives Orphan Drug Designation For Saposin C, The Active Ingredient In BXQ-350 For Glioblastoma Multiforme From FDA 2/16/2015
Soligenix (SNGX) Release: Ricin Toxin Vaccine Poster Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC 2/13/2015
Genzyme (GENZ) Presents Data From Its Phase 1b Program For Niemann-Pick Type B At The Lysosomal Disease Network’s WORLD Symposium 2015 2/13/2015
Verastem, Inc. (VSTM) Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma 2/12/2015
Novavax, Inc. (NVAX) Announces Initiation Of Ebola Vaccine Phase 1 Clinical Trial Supported By Non-Human Primate Challenge Data And Documented Rapid Manufacturing Capabilities 2/12/2015
Oncobiologics Inc. Announces ONS-3010 (Humira/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study 2/12/2015
Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53 2/12/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Meets Primary Endpoint In First Human Clinical Study 2/11/2015
Immune Design Corporation (IMDZ) Announces First Patients Dosed In Phase 1 Clinical Trial Of G100 Investigational Immuno-Oncology Agent 2/11/2015
Ultragenyx Pharmaceuticals (RARE) Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7 2/11/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
Edge Therapeutics Reports Initial Data From Its Phase 1/2 NEWTON Trial For EG-1962 For Improvement Of Outcomes After Ruptured Brain Aneurysm 2/11/2015
Heron Therapeutics, Inc. (APPA) Initiates Phase 1 Clinical Study Of HTX-011 For The Treatment Of Post-Operative Pain 2/11/2015
Theravance Biopharma Initiates Patient Registry Study For VIBATIV(R) (telavancin) 2/11/2015
BIOCEO15: ContraFect (CFRXU) CEO Says Lysin, AB Anti-Infectives Are “Game-Changers” in 2015 2/10/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1b Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection 2/10/2015
Apellis Pharmaceuticals Enters Clinical Testing Phase In Its Age-Related Macular Degeneration Program 2/10/2015
Strategic Science & Technologies Initiates Phase 1 Study To Evaluate Topical Sildenafil In Women With Female Sexual Arousal Disorder 2/9/2015
Alkermes plc (ALKS) Announces Positive Topline Results From Phase 1 Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 2/9/2015
Trevena, Inc. (TRVN) Announces Positive Results From Phase 1 Multiple Ascending Dose Study Of TRV734 For Moderate To Severe Acute And Chronic Pain 2/9/2015
Safety And Preliminary Efficacy Of Human Neural Stem Cells In StemCells (STEM)'s Dry AMD Study To Be Presented At Ophthalmology Conference 2/5/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Non-Small Cell Lung Cancer 2/5/2015
THERAVECTYS Obtains Orphan Drug Designation From European Medicines Agency For Its Lentiviral Vector-Based Therapeutic Vaccine Against Adult T-Cell Leukemia And Lymphoma 2/5/2015
Proteostasis Therapeutics, Inc. Announces A New Class Of Agents For Cystic Fibrosis Called CFTR Amplifiers And Selects PTI130 As A Development Candidate 2/5/2015
Akaal Pharma Announces Positive Results From Phase 1 Clinical Study Of Novel Topical AKP-11 For The Treatment Of Psoriasis 2/5/2015
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus FOLFOX In Advanced Gastrointestinal Malignancies 2/3/2015
bluebird bio (BLUE)'s Rare Blood Disorder Drug Tagged a Breakthrough by the FDA 2/3/2015
bluebird bio (BLUE) Release: FDA Grants Breakthrough Therapy Designation To Lentiglobin For Treatment Of Beta-Thalassemia Major 2/2/2015
Pluristem Therapeutics (PSTI) Announces Significant New Finding From Its Phase I/II Muscle Injury Trial And Excellent Safety Profile For PLX-PAD Cells At Twelve Months 2/2/2015
Protalix Biotherapeutics, Inc. (PLX) Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease 2/2/2015
Bionomics Limited (BNO.AX) Begins Phase 1b Study With Anxiety Drug Bnc210 2/2/2015
Kamada Ltd. (KMDA) Reports Encouraging Interim Data From Its Phase 1/2 Extension Study: AAT In Pediatric Patients With Type 1 Diabetes 2/2/2015
Alnylam Pharmaceuticals (ALNY) Initiates Phase 1/2 Clinical Trial For ALN-CC5, A Subcutaneously Administered Rnai Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases 2/2/2015
Rock Creek Pharmaceuticals Receives Clinical Trial Application Approval 1/30/2015
First Trial Finds GlaxoSmithKline (GSK) Ebola Shot Safe 1/29/2015
XencorReports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction Of Serum Ige In Healthy Volunteers 1/29/2015
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity In Rheumatoid Arthritis 1/29/2015
Celldex Therapeutics, Inc. (CLDX) And Bristol-Myers Squibb Company (BMY) Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors 1/29/2015
Cleveland Biolabs Inc. (CBLI) Announces Oncology Clinical Development Update For Entolimod 1/29/2015
International Stem Cell Corporation To Conduct Parkinson's Disease Clinical Study In Australia 1/29/2015
Endexx Announces Positive Results Of Initial Diabetic Neuropathy Patient Study 1/29/2015
aTyr Pharma Inc. Announces First FSHD Patient Study Of Resolaris™ 1/28/2015
RestorGenex Granted Orphan Drug Designation For RES-529 For Treatment Of Glioblastoma Multiforme 1/28/2015
Sorrento Therapeutics, Inc. Announces Completion Of Enrollment In The Cynviloq™ Registrational TRIBECA™ Study 1/28/2015
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015
Pharmacyte Biotech's Expanded Follow-Up Study On Malignant Ascites Fluid Accumulation In Final Stages Of Preparation 1/26/2015
Cellceutix (CTIX) Plans Clinical Trial In Patients With Ulcerative Proctitis 1/26/2015
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 1/23/2015
Minerva Neurosciences, Inc. (NERV) Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist For Treatment Of Sleep Disorders Including Primary And Comorbid Insomnia 1/22/2015
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2 1/22/2015
Tekmira (TKMR) Initiates Phase I Clinical Trial Of TKM-HBV 1/21/2015
Disneyland Measles Outbreak Casts Shadow on Anti-Vaccination Movement 1/21/2015
Adocia Initiates A Clinical Study On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro Insulin Formulation 1/21/2015
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-391 Ointment For Actinic Keratosis In A Phase 1 Clinical Study 1/20/2015
Tobira Therapeutics Inc. Doses First Subject In Phase 1 Clinical Trial Of Cenicriviroc And Pioglitazone 1/20/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
Immunomedics, Inc. (IMMU) Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) In Patients With Metastatic Gastrointestinal Cancers 1/20/2015
Kite Pharma, Inc. (KITE) Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 1/20/2015
Verastem, Inc. (VSTM) Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 1/20/2015
Cellceutix (CTIX) Reports Spleen Lesion "Disappears" In Patient With Metastatic Stage 4 Ovarian Cancer In Clinical Trial Of Anti-Cancer Drug Kevetrin 1/20/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium 1/19/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
J.P. Morgan: Five Prime Therapeutics, Inc. (FPRX) CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company (BMY) 1/16/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Antibe Therapeutics Inc. (ATE.V) Suspends Its Phase I Clinical Trial Due To Safety Concerns 1/16/2015
Pfizer (PFE)'s Working on Once-a-Year Anti-Cholesterol Shot 1/15/2015
Auspex Pharmaceuticals (ASPX) Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Tourette Syndrome In The Pediatric Population 1/15/2015
OncoMed Pharmaceuticals, Inc. (OMED) Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors 1/15/2015
Novan Therapeutics To Present Successful Clinical Study Results Of Lead Product Candidate SB204 For The Treatment Of Acne Vulgaris 1/15/2015
Newron Pharmaceuticals (NWRN) Announces Results Of Phase I Study Of NW-3509 Phase II Study In Schizophrenia Patients Planned For Q2 2015 1/15/2015
Aptose Biosciences Doses First Patient In Phase 1b Clinical Study Of APTO-253 In Relapsed Or Refractory Hematological Malignancies 1/14/2015
Ascendis Pharma A/S Announces Initiation Of A Phase 1 Single Ascending Dose Study Of Transcon Treprostinil 1/14/2015
Sarepta (SRPT) Announces First Patient Dosed In European Phase1/2 Study Of SRP-4053 In Duchenne Muscular Dystrophy Patients 1/14/2015
BioLine Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 1/14/2015
BioMarin (BMRN) Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study Of BMN 190 For Treatment Of CLN2 Disorder, A Form Of Batten Disease 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015
PsiOxus Therapeutics Limited Release: European Medicines Agency Grants Positive Opinion For Orphan Drug Status For Ovarian Cancer Oncolytic Vaccine 1/13/2015
Bellicum Pharmaceuticals, Inc. Announces Successful Dosing Of First Patient Cohort With BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell Transplant 1/13/2015
Auspex Pharmaceuticals (ASPX) Announces Favorable Topline Results From Thorough QT Clinical Trial Of SD-809 1/12/2015
Lipocine Inc. (LPCN) Announces Positive Phase 1b Top-Line Results With LPCN 1107 In Pregnant Women 1/12/2015
Second Genome Advances Lead Microbiome Drug Development Program In Phase I Clinical Trial As A Treatment For Inflammatory Bowel Disease 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Metastatic Colorectal Cancer 1/12/2015
Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study 1/12/2015
ProteoTech Is Granted Orphan Drug Designation For Systebryl™ (PTI-110) For The Treatment Of AL Amyloidosis 1/12/2015
Scancell To Provide Positive SCIB1 Phase 1/2 Clinical Trial Update During Corporate Presentations 12-15 January, San Francisco 1/12/2015
FDA Approves Cytori Therapeutics, Inc. (CYTX) U.S. Pivotal Scleroderma Trial 1/12/2015
Alnylam Pharmaceuticals (ALNY) Reports Initial Evidence For Potential Correction Of The Hemophilia Phenotype In Phase 1 Study Of ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia 1/12/2015
ReVance Therapeutics, Inc. (RVNC) Announces Publication of Positive Results From RT002 Phase 1/2 Study 1/9/2015
Journal Of Cardiovascular Pharmacology Publishes Positive Nonclinical Results Of Proteon Therapeutics, Inc. (PRTO)'s PRT-201 In Peripheral Artery Disease 1/9/2015
SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus 1/9/2015
TONIX Pharmaceuticals, Inc. (TNXP) Announces Clinical Progress On Potential Treatment for Headache 1/9/2015
Regen BioPharma Identifies Second Generation Gene Silencing Candidates For Blocking Cancer Stem Cell Gene Target 1/9/2015
CoMentis, Inc. And Anvyl Announce The Initiation Of Clinical Trials For APN1125 For The Treatment Of Schizophrenia 1/9/2015
BEAT BioTherapeutics dATP Technology Improves Cardiac Function In End Stage Human Heart Failure Cardiac Muscle 1/9/2015
TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/9/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Interim Data From Phase 1/2 Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease 1/8/2015
Karyopharm Therapeutics (KPTI) Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma 1/8/2015
First Patient Successfully Transplanted With Cryopreserved (Frozen) Nicord® In Gamida Cell Ltd.'s Ongoing Phase I/II Clinical Trial For Blood Cancers 1/8/2015
Cleave Biosciences Initiates Phase 1 Clinical Trial Of CB-5083 In Patients With Advanced Solid Tumors 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology 1/8/2015
Targovax Reports Completion Of Recruitment Of Patients In The Phase 1/2 Clinical Trial CT TG01-01 1/8/2015
Principia Biopharma Successfully Completes Phase 1 Clinical Trial Of PRN1008, A Novel Oral BTK Inhibitor For Autoimmune Diseases 1/8/2015
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 Is Safe With Potential For Therapeutic Effect On Fibrosis In NASH Patients With Advanced Fibrosis 1/7/2015
Arena Pharmaceuticals, Inc. (ARNA) Reports Positive Results From Phase 1b Clinical Trial Evaluating APD334 For The Treatment Of Autoimmune Diseases 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
Cortice Biosciences Announces Enrollment Of A Phase 1 Trial Evaluating TPI 287 Plus Radiotherapy For Treatment Of Lung And Breast Cancer Metastases To The Brain 1/7/2015
Johnson & Johnson (JNJ) Starts Ebola Vaccine Testing in Humans 1/6/2015
Johnson & Johnson (JNJ) Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen 1/6/2015
GliaCure Completes Phase 1a Clinical Trial In Alzheimer's Disease 1/6/2015
Celsion Corporation (CLSN) Submits DNA-Based Immunotherapy Clinical Protocol To The FDA As Part Of A First Line Treatment For Ovarian Cancer 1/6/2015
Inovio Pharmaceuticals (INO) HIV Immunotherapy Shows Characteristics Considered Vital To Treating HIV 1/6/2015
cCAM Biotherapeutics Receives FDA Approval To Initiate Phase 1 Trial For CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 1/6/2015
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 1 Clinical Trial For The Ebola Vaccine Regimen Of MVA-BN® Filo And Janssen's AdVac® technology 1/6/2015
BioLineRx Ltd. Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment 1/6/2015
Cleveland Biolabs Inc. (CBLI) And Incuron Announce Updates On Clinical Progress With Curaxin CBL0137 1/6/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
Anavex Life Sciences Corp. (AVXL) Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor 1/6/2015
Merck & Co. (MRK), NewLink Genetics Ebola Vaccine Trial Resumes in Geneva 1/5/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
OncoMed Pharmaceuticals, Inc. (OMED) Doses First Patient In Phase 1 Clinical Trial Of Novel Anti-DLL4/VEGF Bispecific Antibody 1/5/2015
Alnylam Pharmaceuticals (ALNY) Files Clinical Trial Application To Initiate A Phase 1 Study For ALN-AS1, A Subcutaneously Administered, Investigational Rnai Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias 1/5/2015
Tekmira (TKMR) Provides Update On TKM-PLK1 Phase I/II Clinical Study In Patients With Advanced Gastrointestinal Neuroendocrine Tumors And Adrenocortical Carcinoma 12/31/2014
Idera Pharmaceuticals, Inc. (IDRA) Provides Key Updates On Clinical Development Of IMO-8400 For Treatment Of Waldenstrom's Macroglobulinemia 12/30/2014
Synthetic Biologics, Inc. (SYN) Announces First Patient Dosed In Phase 1b Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/30/2014
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014
AEterna Zentaris (AEZS): Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-361 In A Phase 1 Clinical Study 12/24/2014
Novastem Treats First Patient Using Stemedica Cell Technologies, Inc.'s Mesenchymal And Neural Stem Cell Combination Therapy For Ischemic Stroke 12/24/2014
Mirati Therapeutics  (MRTX) Doses First Patient In Expansion Cohorts Of Phase 1b Trial Of MGCD265 In Genetically Selected Patients 12/23/2014
Helix Biopharma (TSX:HBP) Announces Initiation Of First Clinical Site For US Study 12/23/2014
Tekmira (TKMR) Receives Clearance To Conduct A Phase I Clinical Study With TKM-HBV 12/22/2014
New Published Data Show Pluristem Therapeutics (PSTI)'s PLX Cells Protect Neurons 12/22/2014
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1a Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/22/2014
Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use Of Dermal Sheath Cup Cells To Treat Pattern Baldness 12/22/2014
Relmada Therapeutics Doses First Cohort Of Subjects In Human Clinical Trial Of D-Methadone 12/22/2014
AGA's GERD Registry Enrolls First Patients 12/22/2014
ContraFect Corporation (CFRXU) Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections 12/22/2014
Galapagos NV (GLPG.BR) Initiates First Phase 1 Study In Cystic Fibrosis And Will Receive Milestone Payment From AbbVie (ABBV) 12/19/2014
Curis, Inc. (CRIS) Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors 12/18/2014
Inovio Pharmaceuticals (INO) Initiates DNA Immunotherapy Trial For Breast, Lung And Pancreatic Cancers 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014
Dyax Corp. (DYAX)'s First-In-Human Trial For DX-2930 Conducted By Vince And Associates Clinical Research Featured In The Annals Of Allergy, Asthma & Immunology 12/18/2014
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014
Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data From Phase 1b Trial Of I.V. CR845 In Dialysis Patients 12/17/2014
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors 12/17/2014
Clementia Initiates First Prospective Natural History Study In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 12/17/2014
Capstone Therapeutics (CAPS) Announces Phase 1b/2a Study Results For AEM-28 Showing Safety And Biomarker Efficacy Signals 12/16/2014
TetraLogic Pharmaceuticals (TLOG) Provides Update On Ovarian Cancer Study 12/16/2014
Hemispherx Biopharma (HEB)'s Ampligen® Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
Prothena Receives FDA Fast Track Designation For NEOD001, A Monoclonal Antibody For The Treatment Of Patients With AL Amyloidosis 12/16/2014
Alla Chem Completes Phase Ib/Iia Clinical Study With AV4025, An HCV NS5A Inhibitor 12/16/2014
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase 1 Clinical Trial Of BCX4430 For The Treatment Of Hemorrhagic Fever Viruses 12/15/2014
Cerulean Pharma Inc. (CERU) Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma 12/15/2014
Alkermes plc (ALKS) Announces Initiation Of Clinical Study Of Extended Durations Of Aripiprazole Lauroxil For Treatment Of Schizophrenia 12/15/2014
Complexa Initiates Phase 1B Study Of CXA-10 In Acute Kidney Injury 12/15/2014
Immunomedics, Inc. (IMMU) Reports Expanded Phase 1/2 Trials Confirm Activity And Good Safety Profile Of Sacituzumab Govitecan (Immu-132) In Patients With Advanced Triple-Negative Breast Cancer 12/12/2014
Synta Pharmaceuticals (SNTA) Announces Presentation Of Results From An Investigator-Sponsored Phase 1 Trial Of Ganetespib In HER2+ Metastatic Breast Cancer At The 2014 San Antonio Breast Cancer Symposium 12/12/2014
Oncothyreon Inc. (ONTY) Announces Presentation Of Positive ONT-380 Data At San Antonio Breast Cancer Symposium 12/12/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Sorafenib In Advanced Hepatocellular Carcinoma 12/11/2014
Calithera Biosciences, Inc. (CALA) Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition In Tumor Biopsy Samples From Patients Treated With CB-839 12/11/2014
Vical Incorporated (VICL) Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial 12/11/2014
Radius (RDUS) Presents RAD1901 Data At 2014 San Antonio Breast Cancer Symposium 12/11/2014
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Initiation Of Phase 1 Clinical Trial For ALN-Pcssc, A Subcutaneously Administered Investigational Rnai Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 12/11/2014
Atterocor Expands Phase 1 Trial Of ATR-101 To Additional Leading Adrenal Cancer Centers 12/11/2014
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
bluebird bio (BLUE) Skyrockets Almost 70% On Blood Disease Data 12/10/2014
Arno Therapeutics Doses First Patient In Expansion Stage Of Modified Phase 1/2 Trial Evaluating Onapristone In Progesterone Receptor Positive Tumors 12/10/2014